Today’s Top Three in Pharma 012909

Sepracor cutting 20% of its workforce. Ouch. Sepracor Inc, maker of the Lunesta sleep drug, said on Wednesday it would cut about 20 percent of its workforce, or 530 jobs, in an effort to save some $210 million in expenses, and its shares jumped 17 percent. The company said most of the cuts would come from field-based positions, leaving it with a sales force of about 1,325 after the restructuring moves.

Zoloft and Lexapro – still the ones? Pfizer Inc’s Zoloft and Forest Laboratories Inc’s  Lexapro are the most effective and well-tolerated antidepressants among a group of 12 new drugs, according to an analysis published on Thursday.

The physician sense of entitlement – what do you think? An interesting thought from Daniel Carlat‘s Psychiatry blog.

PLUS – speculation about Bristol being the next acquisition target. Blah, blah, blah…that talk has been around for years. Meanwhile, Novartis not looking at any big deals in the near term.

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Join a Linkedin Pharma Professionals Networking Group.

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs. This “matchmaking” service is provided free to clients.